Australia is showing great interest in the availability of Retatrutide, a novel medication from Novo Nordisk. This twin-action drug, targeting both GLP-1 and GIP receptors, presents significant results in testing, https://imogenywmg984063.wikistatement.com/5913493/novo_nordisk_s_retatrutide_australia_a_potential_solution_for_obesity_treatment